Related Experiment Video

Updated: Jul 4, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Management of malignant glioma--quo vadis?

Roger Stupp, Andreas F Hottinger

    Onkologie
    |June 13, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper
    05:45

    Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper

    Published on: January 19, 2024

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
    08:00

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

    Published on: April 16, 2019

    Related Experiment Videos

    Last Updated: Jul 4, 2026

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper
    05:45

    Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper

    Published on: January 19, 2024

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
    08:00

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

    Published on: April 16, 2019

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Ultrasound-mediated blood-brain barrier modulation enhances T-cell access but requires immune activation for effective CNS immunity.

    bioRxiv : the preprint server for biology·2026

    Association between temozolomide-related hematologic toxicity and health-related quality of life (HRQoL) in patients with newly diagnosed glioblastoma.

    Neuro-oncology·2026

    Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Development of skull-implanted ultrasound for blood-brain barrier opening and drug delivery in neuro-oncology.

    Neuro-oncology advances·2026

    The perinecrotic niche of glioblastoma drives tumor-associated macrophage polarization and immunosuppression via podoplanin-mediated CLEC5A activation.

    The Journal of clinical investigation·2026

    Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.

    Onkologie·2013

    Metastatic germ cell tumour following renal transplantation.

    Onkologie·2013

    miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.

    Onkologie·2013

    A meta-analysis of internal mammary lymph node metastasis in breast cancer patients.

    Onkologie·2013

    Patient-related delay in presentation for cutaneous squamous cell carcinoma. A cross-sectional clinical study.

    Onkologie·2013

    Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.

    Onkologie·2013
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us